Publications

LES PUBLICATIONS :
(2008 Sep;13, Apoptosis) Flt3 receptor inhibition reduces constitutive NFkappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia
Voir le détails
(2008 May;22, Leukemia.)Meeting report: myelodysplastic syndromes at ASH 2007
Voir le détails
(2008 May, Br J Haematol. ) Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia
Voir le détails
(2008 Jul;7, Cell Cycle.) A novel effect of DNA methyltransferase and histone deacetylase inhibitors: NFkappaB inhibition in malignant myeloblasts
Voir le détails
(2008 Jul, Leuk Res.)Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide.
Voir le détails
(2008 Jul 8, Biochem Pharmacol) Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: A preclinical comparison
Voir le détails
(2008 Jul 23, Blood ) Pegylated Interferon-alfa-2a induces complete hematological and molecular responses with low toxicity in Polycythemia Vera.
Voir le détails
(2008 Jul 18, Leuk Res.) Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes.
Voir le détails
(2008 Jul 10, Cancer) Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original international prognostic scoring system
Voir le détails
(2008 Jan 15, Blood) Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience
Voir le détails
(2008 Feb, Br J Haematol) The role of lenalidomide in the management of myelodysplasia with del 5q
Voir le détails
(2007 Nov, Leukemia) Defects of immune surveillance offer new insights into the pathophysiology and therapy of myelodysplastic syndromes.
Voir le détails
(2006 May;20 ,Leukemia) Late first relapses in APL treated with all-trans-retinoic acid- and anthracycline- based chemotherapy: the European APL group experience (APL 91 and APL 93 trials).
Voir le détails
(2005 Jan 27, Blood) Rescue of early stage myelodysplastic syndrome-deriving erythroid precursors by the ectopic expression of a dominant negative form of FADD.
Voir le détails
(2004 Jul 15, Blood.) Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes
Voir le détails
(2004 Hematol J.) A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes.
Voir le détails
(2003 Feb, Leukemia) Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts.
Voir le détails
(2000 Mar;18, J Clin Oncol.) Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantation.
Voir le détails
(1999, Adv Exp Med Biol.) Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP).
Voir le détails
(1999 Apr;13, Leukemia) A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes
Voir le détails
(1998 Sep, Br J Haematol. ) Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study.
Voir le détails